GlassScriptPhysician profile
Jillian M Heisler
NPI 1548614175
$42,963.24
in general payments reported to CMS, 2019-2025
62 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $730 · 2021: $1,115 · 2022: $1,724 · 2023: $10K · 2024: $16K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $13K · Consulting Fee: $1,525 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,900.00 |
| Food and Beverage | $12,761.38 |
| Consulting Fee | $1,525.00 |
| Education | $101.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,464.51 | 2021-2025 | |
| Pfizer INC. | $2,027.27 | 2023-2025 | |
| Imbed Biosciences INC. | $1,994.30 | 2023 | |
| Ucb, INC. | $1,217.93 | 2020-2025 | Briviact, Fintepla, Zilbrysq |
| Genzyme Corporation | $606.09 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $559.25 | 2020-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $536.53 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Celgene Corporation | $524.46 | 2023-2025 | Zeposia |
| Lundbeck LLC | $524.11 | 2021-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $402.90 | 2020-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $399.60 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $386.44 | 2020-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $377.47 | 2023-2025 | |
| Amgen INC. | $371.70 | 2020-2025 | Uplizna |
| Argenx US, INC. | $356.38 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $342.53 | 2023-2025 | Hyqvia |
| Genentech USA, INC. | $327.21 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Biogen, INC. | $318.47 | 2021-2025 | Leqembi, Vumerity, Tysabri |
| Biohaven Pharmaceutical Holding Company LTD. | $314.53 | 2022 | |
| Grifols USA, LLC | $295.88 | 2020-2025 | Gamunex-C |
| Lilly USA, LLC | $282.81 | 2020-2024 | Emgality, Amyvid, Reyvow |
| Biohaven Pharmaceuticals, INC. | $233.65 | 2021 | |
| Livanova USA, INC. | $209.52 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Merz Pharmaceuticals, LLC | $204.52 | 2024-2025 | Xeomin, Inbrija |
| Csl Behring | $204.38 | 2020-2025 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $202.77 | 2021-2024 | |
| Allergan, INC. | $188.36 | 2021-2022 | |
| Janssen Biotech, INC. | $187.73 | 2025 | |
| Octapharma USA, INC. | $145.00 | 2023-2025 | Panzyga |
| Otter Pharmaceuticals, LLC | $136.77 | 2024-2025 | Sympazan |
| Acadia Pharmaceuticals INC | $135.63 | 2024-2025 | Nuplazid, Daybue |
| Averitas Pharma INC. | $126.19 | 2023-2025 | Qutenza |
| Emd Serono, INC. | $117.16 | 2020-2024 | Mavenclad |
| Impel Pharmaceuticals INC. | $107.58 | 2023 | Trudhesa |
| Vanda Pharmaceuticals INC. | $96.49 | 2021-2025 | Ponvory |
| Tg Therapeutics, INC. | $94.51 | 2024-2025 | |
| Impel Pharmaceuticals LLC | $87.16 | 2025 | Trudhesa |
| Acorda Therapeutics, INC | $80.00 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $72.83 | 2021 | |
| Sumitomo Pharma America, INC. | $64.96 | 2023-2024 | Aptiom |
| Azurity Pharmaceuticals, INC. | $64.38 | 2023-2024 | Horizant, Horizant |
| Almatica Pharma LLC | $55.88 | 2021 | |
| Eisai INC. | $49.67 | 2025 | |
| Ge Healthcare | $45.69 | 2024-2025 | |
| Harmony Biosciences LLC | $41.82 | 2025 | |
| Corium, LLC | $40.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $34.03 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $27.44 | 2021-2024 | Andexxa |
| Tanabe Pharma America, INC. | $24.25 | 2025 | Radicava |
| Sk Life Science, INC. | $24.13 | 2024 | |
| Aucta Pharmaceuticals, INC. | $23.90 | 2025 | Motpoly Xr |
| Alnylam Pharmaceuticals INC. | $23.57 | 2024 | Onpattro |
| Akcea Therapeutics, INC. | $22.29 | 2020 | |
| Avanir Pharmaceuticals, INC. | $21.51 | 2022 | |
| Boston Scientific Corporation | $20.67 | 2024 | |
| Amneal Pharmaceuticals LLC | $20.47 | 2022 | |
| Immedica Pharma US, INC. | $19.43 | 2024 | |
| Merck Sharp & Dohme LLC | $18.46 | 2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Upsher-Smith Laboratories LLC | $17.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.27 | 2021 | |
| Axsome Therapeutics, INC. | $14.15 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $13.64 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Heisler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.